Articles tagged "Immunosuppression"

2017 American Transplant Congress
Clinic-Based Medication Education Pilot Program.
N. Sulejmani,¹ H. Albanna,¹ T. Rendulic,² B. Summers,¹ A. Jantz.¹
¹Henry Ford Hospital, Detroit, MI; ²University of Kentucky, Lexington, KY
Purpose: Adherence to medications is crucial for transplant patients as missing medications can result in increased risk of rejection and graft loss. Augmented education may…
2017 American Transplant Congress
Type of Surgical Procedures and Clinical Significance of Calcineurin Inhibitor Temporary Discontinuation Regarding LT Recipients Undergoing Major Elective Surgery.
C. Cho, J. Lee, K. Kim, S. Kim, J. Lee, K. Lee, J.-M. Kim, G.-S. Choi, C. Kwon, J.-W. Joh.
Surgery, Samsung Medical Center, Seoul, Republic of Korea
Background As patients increasingly have undergone live transplantation (LT) and improved expected survival rate, there is a growing population of LT recipient undergoing elective surgery…
2017 American Transplant Congress
Molecular Profiles of Renal Allograft Biopsies at 12 Months Post Renal Transplant in Patients Exposed to Low Dose CNI and Everolimus vs. Patients Exposed to Full Dose CNI and MMF.
L. Gallon,¹ J. Leventhal,¹ D. Maluf,² V. Sai Bontha,² A. Shetty,¹ O. Traitanon,¹ M. Ansari,¹ J. Mathew,¹ S. Wongpraphairot,¹ V. Mas.²
¹Nephrology, Transplant Center, Northwestern University, Chicago; ²University of Virginia, Charlottesville
CNIs serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize that lower…
2017 American Transplant Congress
Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation.
M.-T. Dieterlen, K. Klaeske, J. Fischer, J. Hahn, K. Jawad, J. Garbade, F. Mohr, S. Lehmann.
Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Introduction: The mammalian target of rapamycin (mTOR) is a central regulator of the immune system and therefore one target of immunosuppressive drug therapy. Tolerance-inducing properties…
2017 American Transplant Congress
Utility of Weighted Composite Endpoints in Kidney Transplantation.
J. Schold, D. Goldfarb, S. Flechner, L. Buccini, J. Augustine, E. Poggio.
Cleveland Clinic, Cleveland, OH
IntroductionAdvances in therapeutic development and innovation are stifled in transplantation based on difficulties demonstrating efficacy of novel interventions using standard endpoints. Current RCTs are constrained…
2017 American Transplant Congress
Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.
M. Okada,¹ Y. Watarai,¹ K. Iwasaki,² K. Murotani,³ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Renal Transplant Surgery, Aichi Medical University, Nagakute, Japan; ³Clinical Research Center, Aichi Medical University, Nagakute, Japan
BACKGROUNDPretransplant desensitization with rituximab has contributed to drastic improvements in ABO-incompatible renal transplantation (ABO-I). However, ABO-I outcomes are still worse than those of ABO-identical or…
2017 American Transplant Congress
Risk Factors for Polyomavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis.
S. Hosseini-Moghaddam, Q. Xu, J. Kum, H. Alharbi, A. Jevnikar, M. John, G. Singh, S. Parsons, M. Edgar, P. Luke.
Medicine, Western University, London Health Sciences Centre, London, ON, Canada
Objective: To determine the roles of pre and post-transplant variables on the risk of BK virus infection after renal transplantation.Method: This study is a single-…
2017 American Transplant Congress
The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database.
Q. Liu,¹ A. Smith,¹ J. Park,² M. Oguntimein,³ S. Dutcher,³ G. Bello,¹ M. Helmuth,¹ M. Turenne,¹ R. Balkrishnan,⁴ M. Fava,¹ P. Sharma,² C. Beil,¹ A. Leichtman,¹ J. Zee.¹
¹Arbor Research Collaborative for Health, Ann Arbor, MI; ²U of Michigan, Ann Arbor, MI; ³Food and Drug Administration, Silver Spring, MD; ⁴U of Virginia, Charlottesville, VA
Background: Substitution of generic for brand-name immunosuppressants has increased in solid organ transplantation following the expiration of brand patents. Our aim was to describe the…
2017 American Transplant Congress
The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response.
N. Murakami,¹ T. Win,¹ T. Borges,¹ C. Lian,¹ G. Murphy,¹ E. Bueno,¹ R. Clark,¹ T. Strom,² B. Pomahac,¹ L. Riella.¹
¹Brigham and Women's Hospital, Boston; ²Beth Israel Deaconess Medical Center, Boston
BackgroundRegulatory T cells (Tregs) play a critical role in immune tolerance and low-dose recombinant IL-2 administration has been reported to expand Tregs in vivo. Although…
2017 American Transplant Congress
Is There a Role for Electronic Health Service in of Therapeutic Drug Monitoring of Immunosuppression?
M. Barten,¹ I. Hausladen,² F. Mohr, J. Garbade.
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²Cardiac Surgery, University Hospital Leipzig, Heart Center, Leipzig, Germany
Background: Therapeutic drug monitoring (TDM) of immunosuppression is critical to avoid rejection or toxic side effects by under- or over-immunosuppression after heart transplantation (HTx). Hence,…